UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450

NOTICE OF ALLOWANCE AND FEE(S) DUE

28008 7590 01/31/2008

DNAX RESEARCH INC. LEGAL DEPARTMENT 901 CALIFORNIA AVENUE PALO ALTO, CA 94304 EXAMINER SEHARASEYON, JEGATHEESAN

PAPER NUMBER

ART UNIT

1647 DATE MAILED: 01/31/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/720,026	11/21/2003	Madaline Chirica	DX01074B1K	3154

TITLE OF INVENTION: MAMMALIAN RECEPTOR PROTEIN DCRS5;METHODS OF TREATMENT

APPLN, TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0	\$1740	04/30/2008

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT, PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and I/2 the ISSUE FFE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where

appropriate. All further indicated unless corrects maintenance fee notifica	correspondence includir ed below or directed oth tions	ng the Patent, advance nerwise in Block 1, by	orders and notification y (a) specifying a new c	of n	naintenance fees w pondence address;	ill be and/o	mailed to the current (b) indicating a sepa	com	espondence address as "FEE ADDRESS" for
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)				Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.					
DNAX RESEA LEGAL DEPAR 901 CALIFORN	ARCH INC. RTMENT NA AVENUE	/2008			Cert	ificate	of Mailing or Trans	missi g dep st cla abov ate ir	ion osited with the United ss mail in an envelope re, or being facsimile adicated below.
PALO ALTO, C	CA 94304								(Depositor's name)
									(Signature)
				L					(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVEN	NTOR ATT		ATTO	RNEY DOCKET NO.	CC	ONFIRMATION NO.
10/720,026	11/21/2003		Madaline Chirica				DX01074B1K		3154
			RS5;METHODS OF TRE						D. C. D. C.
APPLN, TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE D	OUE	PREV. PAID ISSUE	FEE	TOTAL FEE(S) DUE	_	DATE DUE
nonprovisional	NO	\$1440	\$300	_	\$0 1		\$1740		04/30/2008
EXAM		ART UNIT	CLASS-SUBCLASS	SS					
SEHARASEYON.		I647	424-143100		atent front page, lis				
I. Change of correspondence address or indication of "Fee Address" (37 CFR 1.853). Change of correspondence address for Change of Correspondence Address from PIOSB/123 jautched. The Address from PIOSB/123 jautched. The Address' indication for "Fee Address" indication from PITOSB/147 jautched. Use of a Customer Service of the Address from PIOSB/147 jautched. Use of a Customer Number is required. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON			e or agents OR, alter (2) the name of a registered attorney 2 registered patent listed, no name wil	(1) the aames of up 6.3 registered patent attorneys or agent 0.8 Rallernatively, (2) the name of a single firm flaving as a member a 2 registered patent attorneys or agents. If no name is 3 listed, no name will be printed					
PLEASE NOTE: Uni recordation as set fort (A) NAME OF ASSI	less an assignee is ident h in 37 CFR 3.11. Comp GNEE	ified below, no assign pletion of this form is N	tee data will appear on the NOT a substitute for filing (B) RESIDENCE: (C) printed on the patent):	he pa g an a	atent. If an assigne assignment. and STATE OR C	OUNT	'RY)		
		categories (will not be				_			•
4a. The following fee(s) Issue Fee Publication Fee (N Advance Order -	A check is enclos Payment by credi	th. Payment of Fee(s): (Pfease first reapply any previously paid issue fee shown above) A check is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number (enclose an extra copy of this form).							
	s SMALL ENTITY state	as. See 37 CFR I.27.					ITTY status. Sec 37 Cl		
NOTE: The Issue Fee an interest as shown by the	d Publication Fee (if req records of the United Sta	uired) will not be acceptes Patent and Tradem	pted from anyone other th ark Office.	han th	he applicant; a regi	stered	attorney or agent; or th	ne ass	signee or other party in
Authorized Signature					Date				
Typed or printed name				Registration No.					
This collection of inform an application. Confiden submitting the complete this form and/or suggesti Box 1450, Alexandria, V Alexandria, Virginia 223	nation is required by 37 C tiality is governed by 35 d application form to the ions for reducing this but 'irginia 22313-1450. DC k13-1450.	CFR 1.311. The inform U.S.C. 122 and 37 CF USPTO. Time will v rden, should be sent to O NOT SEND FEES O	ation is required to obtain FR 1.14. This collection is ary depending upon the is the Chief Information O R COMPLETED FORM	n or n is est indiv Office IS TO	etain a benefit by the imated to take 12 m idual case. Any co r, U.S. Patent and D THIS ADDRESS	ne pub ninute: mment Frader . SEN	tic which is to file (and to complete, including s on the amount of tire ark Office, U.S. Deptor of the complete of the comple	i by i ig ga ne ye artme for P	the USPTO to process) thering, preparing, and ou require to complete ent of Commerce, P.O. atents, P.O. Box 1450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

DATE MAILED: 01/31/2008

APPLICATION NO.	FILING DATE	FILING DATE FIRST NAMED INVENTOR		CONFIRMATION NO.	
10/720,026	11/21/2003	Madaline Chirica	DX01074B1K	3154	
28008 75	90 01/31/2008		EXAMINER		
DNAX RESEAR	CH INC.	SEHARASEYON, JEGATHEESAN			
LEGAL DEPARTM		ART UNIT	PAPER NUMBER		
901 CALIFORNIA AVENUE PALO ALTO CA 94304			1647		

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 611 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 611 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Notice of Allowability

Application No.	Applicant(s)	
10/720,026	CHIRICA ET AL.	
Examiner	Art Unit	
legatheesan Seharasevon Ph D	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address-All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

- This communication is responsive to 11/8/2007.
- The allowed claim(s) is/are 1,3,6 and 22-26.
- 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 - 1.

 Certified copies of the priority documents have been received.
 - 2. Certified copies of the priority documents have been received in Application No. _____
 - Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 - * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

- 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
- 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- 1. Notice of References Cited (PTO-892)
- 2.
 Notice of Draftperson's Patent Drawing Review (PTO-948)
- Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 11/8/2007.
- Examiner's Comment Regarding Requirement for Deposit of Biological Material
- 5. Notice of Informal Patent Application
- Interview Summary (PTO-413), Paper No./Mail Date .
- 7. X Examiner's Amendment/Comment
- 8. Examiner's Statement of Reasons for Allowance
- 9. ☐ Other .

/Christine J Saoud/ Primary Examiner, Art Unit 1647 Application/Control Number: 10/720,026 Page 2

Art Unit: 1647

DETAILED ACTION

This Office Action is in response to Applicant's response and amendments filed 11/8/2007. Claims 1, 3, 5, 6, 8 and 9 are pending. Claims 2 and 4 remain withdrawn. Applicant has amended claims 1 and 6. Claims 5, 8 and 9 are cancelled. Claims 18-26 are newly added. However, claims 18-21 also remain withdrawn.

EXAMINER'S AMENDMENT

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Gregory R. Bellomy on 1/7/08.

In the claims

- 3. Please amend the claim 1. Please cancel claims 2, 4, and 18-21:
- 1. (Currently amended) A method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an antagonist of antibody that specifically binds to DCRS5 (SEQ ID NO: 2), or antigen binding fragment thereof, wherein the disorder comprises:
- a) [rheumatoid arthritis:

Page 3

Application/Control Number: 10/720,026

Art Unit: 1647

b) asthma or allergy;

- c) chronic obstructive pulmonary disorder (COPD);
- d) an interstitial lung disorder;
- e)] an inflammatory bowel disorder (IBD)[; or
- f) an inflammatory skin disorder].
 - 4. Claims 1, 3, 6 and 22-26 are allowed.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jegatheesan Seharaseyon, Ph.D whose telephone number is 571-272-0892. The examiner can normally be reached on M-F: 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao, Ph. D can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/720,026 Page 4

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christine J Saoud/ Primary Examiner, Art Unit 1647

JS Art Unit 1647, January 22nd, 2007